Technology Solutions

Biotheranostics, Syapse collaborate on precision medicine

Tuesday, September 27, 2016

Biotheranostics, a pioneer in molecular diagnostics for cancer, and Syapse, a precision medicine software provider, plans to integrate data from Biotheranostics’ CancerTYPE ID and Breast Cancer IndexSM genomic tests into the Syapse Precision Medicine Platform. The software-based service is part of Syapse’s Global Partner Program that aims to leverage strong collaborators toward an integrative approach to precision medicine.

[Read More]

Bracket randomizes first patient using integrated precision block technology

Tuesday, September 20, 2016

Bracket, a clinical trial technology and specialty services provider, has randomized its first patient using Precision Block Design (PBD) technology integrated in its clinical IRT platform, including its mobile application. The first RTSM provider to develop and utilize the novel PBD method, Bracket is minimizing selection bias, reducing predictability of treatments and improving patient randomization by balancing known and unknown prognostic factors across comparative groups.

[Read More]

Inspirata acquires Precision Medicine Network

Wednesday, September 14, 2016

Cancer diagnostics and digital pathology workflow solution provider Inspirata has acquired the assets of Boston-based Precision Medicine Network, including its products and the associated intellectual property. This includes “Crosswalk Insight: Oncology,” a precision medicine knowledge visualization and decision support platform. Inspirata plans to integrate Crosswalk with its Digital Pathology Cockpit and its Cancer Information Data Trust (CIDT) to enhance the precision medicine tools and services available in these products.

[Read More]

Federal prize competition seeks innovative ideas to combat antimicrobial resistance

Tuesday, September 13, 2016

A federal prize competition launched calling for innovative ideas for rapid, point-of-care laboratory diagnostic tests to combat the development and spread of drug resistant bacteria, a rising public health threat. Antibiotic resistant bacteria cause at least 2 million infections and 23,000 deaths each year in the U.S., according to the Centers for Disease Control and Prevention.

[Read More]

Certara acquires d3 Medicine

Thursday, September 8, 2016

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, has acquired d3 Medicine. d3 Medicine, which is based in Parsippany, New Jersey, and Melbourne, Australia, provides strategic planning and stewardship of complex drug development programs.

[Read More]